

## NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

## Health Technology Appraisal

**Pegylated interferon alfa and ribavirin for the treatment of mild chronic hepatitis C – part review of existing guidance no. 75**

**Response to consultee and commentator comments on the provisional matrix of consultees and commentators**

<b>Technical Lead:</b> Alastair Fischer	<b>Executive Lead:</b> Andrew Dillon	<b>Project Manager:</b> Alana Miller		
<b>Version of matrix of consultees and commentators reviewed:</b> Provisional matrix of consultees and commentators sent for consultation				
<b>Date:</b> 22/12/047				
<b>Summary of comments, action taken, and justification of action:</b>				
	Proposed consultee/commentator:	Proposal made by:	Action taken:	Justification:

## APPENDIX F

1.	British Association of the Study of the Liver (BASL)	Roche Products Limited	<input type="checkbox"/> Removed <input checked="" type="checkbox"/> Added <input type="checkbox"/> Queried	<p>Roche requested that BASL participate as a consultee rather than a commentator. BASL was a consultee on the 7<sup>th</sup> wave pegylated interferon alpha 2a &amp; alpha 2b for Hepatitis C appraisal– from investigation of their web site they seem to be a professional rather than research organisation and the change has been agreed.</p>
2.	British Society of Gastroenterology (BSG)	Roche Products Limited	<input type="checkbox"/> Removed <input checked="" type="checkbox"/> Added <input type="checkbox"/> Queried	<p>Roche requested that British Society of Gastroenterology be included as a consultee. BSG was a consultee on the 7<sup>th</sup> wave pegylated interferon alpha 2a &amp; alpha 2b for Hepatitis C appraisal. They have an interest in the area and therefore should be included.</p>